Gedatolisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Gedatolisib. Educational only — not medical advice.
Labeled uses
REVTORPYK is indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting [see Dosage and Administration (2.1) and Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set 959d73ef…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.